Caplin Point Laboratories Limited (CAPLIPOINT.NS)
INR 1869.4
(9.08%)
INR 1869.4
(9.08%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -5.5 Billion INR | -219.55% |
| 2022 | -1.72 Billion INR | 62.09% |
| 2021 | -4.54 Billion INR | -3.66% |
| 2020 | -4.38 Billion INR | -153.47% |
| 2019 | -1.73 Billion INR | -15.26% |
| 2018 | -1.5 Billion INR | -95.88% |
| 2017 | -766.37 Million INR | 17.02% |
| 2016 | -923.51 Million INR | -43.07% |
| 2015 | -645.48 Million INR | -45.24% |
| 2014 | -444.42 Million INR | -79.91% |
| 2013 | -247.02 Million INR | -85.72% |
| 2012 | -133.01 Million INR | 46.9% |
| 2011 | -250.49 Million INR | -112.59% |
| 2010 | -117.83 Million INR | -175.87% |
| 2009 | -42.71 Million INR | 48.79% |
| 2008 | -83.4 Million INR | -1420.33% |
| 2007 | 6.31 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | 100.0% |
| 2023 Q3 | 6.87 Billion INR | 611.0% |
| 2023 Q4 | -5.5 Billion INR | -180.12% |
| 2023 Q2 | -1.34 Billion INR | -118.57% |
| 2023 FY | -5.5 Billion INR | -219.55% |
| 2023 Q1 | 7.24 Billion INR | 520.39% |
| 2022 Q1 | 5.14 Billion INR | 213.28% |
| 2022 Q2 | -3.71 Billion INR | -172.1% |
| 2022 Q3 | 6.01 Billion INR | 262.12% |
| 2022 Q4 | -1.72 Billion INR | -128.63% |
| 2022 FY | -1.72 Billion INR | 62.09% |
| 2021 Q2 | -2.54 Billion INR | -154.15% |
| 2021 Q1 | 4.7 Billion INR | 207.19% |
| 2021 Q3 | 5.62 Billion INR | 320.89% |
| 2021 Q4 | -4.54 Billion INR | -180.85% |
| 2021 FY | -4.54 Billion INR | -3.66% |
| 2020 FY | -4.38 Billion INR | -153.47% |
| 2020 Q1 | 2.83 Billion INR | 263.94% |
| 2020 Q2 | -595.2 Million INR | -120.98% |
| 2020 Q4 | -4.38 Billion INR | -198.97% |
| 2020 Q3 | 4.43 Billion INR | 844.54% |
| 2019 Q3 | 2.44 Billion INR | 507.27% |
| 2019 Q2 | -601.27 Million INR | -127.01% |
| 2019 Q1 | 2.22 Billion INR | 248.29% |
| 2019 Q4 | -1.73 Billion INR | -170.66% |
| 2019 FY | -1.73 Billion INR | -15.26% |
| 2018 Q3 | 1.06 Billion INR | 1473.14% |
| 2018 Q4 | -1.5 Billion INR | -241.28% |
| 2018 FY | -1.5 Billion INR | -95.88% |
| 2018 Q2 | -77.37 Million INR | -109.16% |
| 2018 Q1 | 845.01 Million INR | 210.26% |
| 2017 Q4 | -766.37 Million INR | -197.8% |
| 2017 FY | -766.37 Million INR | 17.02% |
| 2017 Q3 | 783.61 Million INR | 227.22% |
| 2017 Q2 | -615.97 Million INR | -163.32% |
| 2017 Q1 | 972.74 Million INR | 205.05% |
| 2016 FY | -923.51 Million INR | -43.07% |
| 2016 Q4 | -925.99 Million INR | -200.91% |
| 2016 Q3 | 917.65 Million INR | 200.61% |
| 2016 Q2 | -912.04 Million INR | -233.92% |
| 2016 Q1 | 681.01 Million INR | 205.5% |
| 2015 FY | -645.48 Million INR | -45.24% |
| 2015 Q1 | -444.42 Million INR | -205.1% |
| 2015 Q2 | -642.64 Million INR | -44.6% |
| 2015 Q3 | -642.64 Million INR | 0.0% |
| 2015 Q4 | -645.48 Million INR | -0.44% |
| 2014 Q4 | 422.85 Million INR | 203.92% |
| 2014 FY | -444.42 Million INR | -79.91% |
| 2014 Q1 | -247.02 Million INR | -184.36% |
| 2014 Q2 | 268.24 Million INR | 208.59% |
| 2014 Q3 | -406.92 Million INR | -251.7% |
| 2013 Q1 | -133.01 Million INR | -148.3% |
| 2013 Q4 | 292.81 Million INR | 209.65% |
| 2013 FY | -247.02 Million INR | -85.72% |
| 2013 Q3 | -267.05 Million INR | -258.6% |
| 2013 Q2 | 168.38 Million INR | 226.59% |
| 2012 Q3 | -234.68 Million INR | 0.0% |
| 2012 Q1 | -250.49 Million INR | 0.0% |
| 2012 FY | -133.01 Million INR | 46.9% |
| 2012 Q4 | 275.4 Million INR | 217.35% |
| 2011 FY | -250.49 Million INR | -112.59% |
| 2010 FY | -117.83 Million INR | -175.87% |
| 2009 FY | -42.71 Million INR | 48.79% |
| 2008 FY | -83.4 Million INR | -1420.33% |
| 2007 FY | 6.31 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 242.469% |
| Hester Biosciences Limited | 2.29 Billion INR | 340.433% |
| Aarti Drugs Limited | 5.54 Billion INR | 199.266% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 310.869% |
| Albert David Limited | -278.36 Million INR | -1878.561% |
| Alembic Limited | 66.9 Million INR | 8332.735% |
| Alkem Laboratories Limited | -1.6 Billion INR | -242.221% |
| Bafna Pharmaceuticals Limited | 229.93 Million INR | 2495.35% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 266.953% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | -29758.506% |
| Brooks Laboratories Limited | 49.48 Million INR | 11230.039% |
| Eris Lifesciences Limited | 13.8 Billion INR | 139.892% |
| FDC Limited | -57.75 Million INR | -9436.813% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | -93.752% |
| Gufic Biosciences Limited | 3.19 Billion INR | 272.422% |
| Hikal Limited | 7.96 Billion INR | 169.131% |
| Ind-Swift Limited | 9.5 Billion INR | 157.923% |
| Innova Captab Limited | 2.33 Billion INR | 336.001% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | -400.109% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | -296.257% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 120.345% |
| Lincoln Pharmaceuticals Limited | -127.63 Million INR | -4215.094% |
| Lupin Limited | 19.38 Billion INR | 128.412% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 664.423% |
| Medico Remedies Limited | 78.67 Million INR | 7100.394% |
| Morepen Laboratories Limited | -231.17 Million INR | -2282.491% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 189.45% |
| Orchid Pharma Limited | -1.31 Billion INR | -319.205% |
| Procter & Gamble Health Limited | -2.34 Billion INR | -134.57% |
| RPG Life Sciences Limited | -364.7 Million INR | -1410.2% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 4688.259% |
| Sigachi Industries Limited | 859.94 Million INR | 740.468% |
| Solara Active Pharma Sciences Limited | 10.03 Billion INR | 154.902% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 3899.043% |
| Themis Medicare Limited | 764.96 Million INR | 819.997% |
| Unichem Laboratories Limited | 931.91 Million INR | 691.008% |
| Vaishali Pharma Limited | 119.13 Million INR | 4723.075% |
| Wanbury Limited | 1.1 Billion INR | 598.04% |
| Windlas Biotech Limited | -273.04 Million INR | -1917.177% |
| ZIM Laboratories Limited | 983.6 Million INR | 659.951% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | -32.618% |
| Ipca Laboratories Limited | 11.41 Billion INR | 148.249% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 92.4% |
| Venus Remedies Limited | -267.7 Million INR | -1957.415% |
| Sakar Healthcare Limited | 790.93 Million INR | 796.351% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 249.127% |
| Divi's Laboratories Limited | -39.77 Billion INR | 86.151% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | -9.881% |
| Mankind Pharma Limited | -1.74 Billion INR | -215.023% |
| Sequent Scientific Limited | 4.17 Billion INR | 231.806% |
| Laurus Labs Limited | 24.35 Billion INR | 122.612% |
| Neuland Laboratories Limited | -214.05 Million INR | -2472.994% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 295.225% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | -28.527% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 240.79% |
| Amrutanjan Health Care Limited | -248.79 Million INR | -2113.777% |
| Wockhardt Limited | 18.27 Billion INR | 130.146% |
| Bal Pharma Limited | 1.26 Billion INR | 535.887% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 142.652% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | -375.724% |
| Par Drugs and Chemicals Limited | -366.53 Million INR | -1402.623% |
| Shilpa Medicare Limited | 9.06 Billion INR | 160.728% |
| Valiant Laboratories Limited | 649.9 Million INR | 947.466% |
| Ajanta Pharma Limited | -954.9 Million INR | -476.783% |
| Aarey Drugs & Pharmaceuticals Limited | 297.57 Million INR | 1950.835% |
| Granules India Limited | 9.28 Billion INR | 159.307% |
| Medicamen Biotech Limited | 160.31 Million INR | 3535.527% |
| Syncom Formulations (India) Limited | 46.21 Million INR | 12018.591% |
| Piramal Enterprises Limited | 491.39 Billion INR | 101.121% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 117.303% |
| NATCO Pharma Limited | -5.81 Billion INR | 5.317% |
| Suven Life Sciences Limited | -1.63 Billion INR | -237.337% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 384.942% |
| Strides Pharma Science Limited | 23.25 Billion INR | 123.682% |
| Indoco Remedies Limited | 6.47 Billion INR | 185.044% |
| Alpa Laboratories Limited | 35.36 Million INR | 15674.753% |
| Lasa Supergenerics Limited | 205.79 Million INR | 2776.252% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | -484.806% |